Novogen Ltd - Report of Foreign Issuer (6-K)
August 12 2008 - 6:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of August, 2008
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf
by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
11 August, 2008
ASX
& MEDIA RELEASE
11
AUGUST 2008
MARSHALL
EDWARDS, INC., TO PRESENT AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH
CONFERENCE.
Novogen
Limited’s subsidiary, Marshall Edwards, Inc., (Nasdaq: MSHL) has just made the
following announcement.
New
Canaan CT and Sydney Australia – 11 August, 2008 - Marshall Edwards, Inc.,
(NASDAQ:MSHL) will present at the Canaccord Adams 28th Annual Global Growth
Conference on Wednesday 13 August, 2008.
About
Marshall Edwards, Inc.
Marshall
Edwards, Inc., is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics. Marshall Edwards, Inc.
has licensed rights from Novogen Limited (ASX:NRT) (Nasdaq: NVGN) to bring three
oncology drugs -- phenoxodiol, triphendiol and NV-143 -- to market globally. The
Company's lead investigational drug, phenoxodiol, is in a Phase III
multinational multi-centered clinical trial for patients with recurrent ovarian
cancer. More information on the trial can be found at
http://www.OVATUREtrial.com.
Marshall
Edwards, Inc. is majority owned by Novogen Limited (ASX:NRT) (Nasdaq: NVGN), an
Australian biotechnology company that is specializing in the development of
therapeutics based on a flavonoid technology platform. Novogen is developing a
range of therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases. More information on phenoxodiol and on the Novogen group
of companies can be found at www.marshalledwardsinc.com and
www.novogen.com.
Under
U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials and approved by the U.S. Food and Drug Administration (“FDA”) as
being safe and effective for the intended use. Statements included in this press
release that are not historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual results could
differ materially from those contained in the forward-looking statements, which
are based on management's current expectations and are subject to a number of
risks and uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays in the
development and/or FDA approval, or the failure to obtain such approval, of our
product candidates; uncertainties in clinical trial results; our inability to
maintain or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution of any
products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024
